Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of the company's common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 1, 2024, Daniel Bradbury, a director of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• The transactions involved multiple sales at varying prices, ranging from $33.30 to $35.38 per share.
• The sales were conducted through direct holdings and indirect holdings via BioBrit, LLC, Daniel Bradbury Irrevocable Descendant's Trust, Annette Bradbury Irrevocable Descendant's Trust, and The Bradbury Family Trust.
• Following the reported transactions, Bradbury continues to hold shares both directly and indirectly through various entities and trusts.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of insider trading.

Stakeholder Impact

• The share sales by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates